Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies

Maurie Markman, Howard Homesley, D. Andra Norberts, Julian Schink, Fouad Abbas, Antonius Miller, John Soper, Nelson Teng, Neel Hammond, Franco Muggia, Mervyn Israel, Trevor Sweatman

Research output: Contribution to journalArticle

Abstract

AD-32 (N-trifluoroacetyladriamycin-14-valerate), an analogue of doxorubicin, was examined for intraperitoneal (ip) administration in a phase 2 trial involving 25 patients with advanced gynecologic malignancies. At an AD-32 dose of 600 mg/m2, the limiting toxicity was grade 4 neutropenia (64% of patients), while severe abdominal pain was relatively uncommon (12%). Intraperitoneal AD-32 administration was associated with a 200-fold pharmacokinetic advantage for cavity exposure, compared to the systemic compartment. At the 600 mg/m2 dose level, 4 of 9 patients (44%) with ascites experienced control of malignant fluid reaccumulation. Based on the results of this phase 1 trial, further exploration of a possible role for the ip administration of AD-32 in individuals with gynecological malignancies appears indicated, particularly in patients with either small volume residual disease after initial systemic chemotherapy or in those with intractable ascites.

Original languageEnglish (US)
Pages (from-to)90-93
Number of pages4
JournalGynecologic Oncology
Volume61
Issue number1
DOIs
StatePublished - Apr 1996
Externally publishedYes

Fingerprint

valrubicin
Neoplasms
Ascites
Residual Volume
Neutropenia
Doxorubicin
Abdominal Pain
Pharmacokinetics
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Markman, M., Homesley, H., Norberts, D. A., Schink, J., Abbas, F., Miller, A., ... Sweatman, T. (1996). Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecologic Oncology, 61(1), 90-93. https://doi.org/10.1006/gyno.1996.0102

Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. / Markman, Maurie; Homesley, Howard; Norberts, D. Andra; Schink, Julian; Abbas, Fouad; Miller, Antonius; Soper, John; Teng, Nelson; Hammond, Neel; Muggia, Franco; Israel, Mervyn; Sweatman, Trevor.

In: Gynecologic Oncology, Vol. 61, No. 1, 04.1996, p. 90-93.

Research output: Contribution to journalArticle

Markman, M, Homesley, H, Norberts, DA, Schink, J, Abbas, F, Miller, A, Soper, J, Teng, N, Hammond, N, Muggia, F, Israel, M & Sweatman, T 1996, 'Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies', Gynecologic Oncology, vol. 61, no. 1, pp. 90-93. https://doi.org/10.1006/gyno.1996.0102
Markman M, Homesley H, Norberts DA, Schink J, Abbas F, Miller A et al. Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecologic Oncology. 1996 Apr;61(1):90-93. https://doi.org/10.1006/gyno.1996.0102
Markman, Maurie ; Homesley, Howard ; Norberts, D. Andra ; Schink, Julian ; Abbas, Fouad ; Miller, Antonius ; Soper, John ; Teng, Nelson ; Hammond, Neel ; Muggia, Franco ; Israel, Mervyn ; Sweatman, Trevor. / Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. In: Gynecologic Oncology. 1996 ; Vol. 61, No. 1. pp. 90-93.
@article{55e62b84ee8b461b8eb61939deeb9885,
title = "Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies",
abstract = "AD-32 (N-trifluoroacetyladriamycin-14-valerate), an analogue of doxorubicin, was examined for intraperitoneal (ip) administration in a phase 2 trial involving 25 patients with advanced gynecologic malignancies. At an AD-32 dose of 600 mg/m2, the limiting toxicity was grade 4 neutropenia (64{\%} of patients), while severe abdominal pain was relatively uncommon (12{\%}). Intraperitoneal AD-32 administration was associated with a 200-fold pharmacokinetic advantage for cavity exposure, compared to the systemic compartment. At the 600 mg/m2 dose level, 4 of 9 patients (44{\%}) with ascites experienced control of malignant fluid reaccumulation. Based on the results of this phase 1 trial, further exploration of a possible role for the ip administration of AD-32 in individuals with gynecological malignancies appears indicated, particularly in patients with either small volume residual disease after initial systemic chemotherapy or in those with intractable ascites.",
author = "Maurie Markman and Howard Homesley and Norberts, {D. Andra} and Julian Schink and Fouad Abbas and Antonius Miller and John Soper and Nelson Teng and Neel Hammond and Franco Muggia and Mervyn Israel and Trevor Sweatman",
year = "1996",
month = "4",
doi = "10.1006/gyno.1996.0102",
language = "English (US)",
volume = "61",
pages = "90--93",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies

AU - Markman, Maurie

AU - Homesley, Howard

AU - Norberts, D. Andra

AU - Schink, Julian

AU - Abbas, Fouad

AU - Miller, Antonius

AU - Soper, John

AU - Teng, Nelson

AU - Hammond, Neel

AU - Muggia, Franco

AU - Israel, Mervyn

AU - Sweatman, Trevor

PY - 1996/4

Y1 - 1996/4

N2 - AD-32 (N-trifluoroacetyladriamycin-14-valerate), an analogue of doxorubicin, was examined for intraperitoneal (ip) administration in a phase 2 trial involving 25 patients with advanced gynecologic malignancies. At an AD-32 dose of 600 mg/m2, the limiting toxicity was grade 4 neutropenia (64% of patients), while severe abdominal pain was relatively uncommon (12%). Intraperitoneal AD-32 administration was associated with a 200-fold pharmacokinetic advantage for cavity exposure, compared to the systemic compartment. At the 600 mg/m2 dose level, 4 of 9 patients (44%) with ascites experienced control of malignant fluid reaccumulation. Based on the results of this phase 1 trial, further exploration of a possible role for the ip administration of AD-32 in individuals with gynecological malignancies appears indicated, particularly in patients with either small volume residual disease after initial systemic chemotherapy or in those with intractable ascites.

AB - AD-32 (N-trifluoroacetyladriamycin-14-valerate), an analogue of doxorubicin, was examined for intraperitoneal (ip) administration in a phase 2 trial involving 25 patients with advanced gynecologic malignancies. At an AD-32 dose of 600 mg/m2, the limiting toxicity was grade 4 neutropenia (64% of patients), while severe abdominal pain was relatively uncommon (12%). Intraperitoneal AD-32 administration was associated with a 200-fold pharmacokinetic advantage for cavity exposure, compared to the systemic compartment. At the 600 mg/m2 dose level, 4 of 9 patients (44%) with ascites experienced control of malignant fluid reaccumulation. Based on the results of this phase 1 trial, further exploration of a possible role for the ip administration of AD-32 in individuals with gynecological malignancies appears indicated, particularly in patients with either small volume residual disease after initial systemic chemotherapy or in those with intractable ascites.

UR - http://www.scopus.com/inward/record.url?scp=0029969265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029969265&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.0102

DO - 10.1006/gyno.1996.0102

M3 - Article

VL - 61

SP - 90

EP - 93

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -